Нестероидные противовоспалительные препараты и ацетилсалициловая кислота. Есть ли нерешенные вопросы?
- Авторы: Родионов А.В1
-
Учреждения:
- ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
- Выпуск: Том 15, № 2 (2013)
- Страницы: 67-70
- Раздел: Статьи
- URL: https://ogarev-online.ru/2075-1753/article/view/93782
- ID: 93782
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаСписок литературы
- Насонов Е.Л. Нестероидные противовоспалительные препараты: Перспективы применения в медицине. М.: Анко, 2000.
- Насонов Е.Л. Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы. Клин. фармакология и терапия. 2000; 1: 57–64.
- Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009.
- FitzGerald G.A., Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42.
- McAdam B.F., Catella-Lawson F, Mardini I.A. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitors of COX-2. PNAS 1999; 96: 272–7.
- Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal. Arthritis Rheum 2003; 48: 12–20.
- Marcus A.J., Broekman M.J., Pinsky G.J. COX inhibition and thromboregulation. N Engl J Med 2002; 347: 1025–6.
- White W.B., Faich G, Whelton A. et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase–2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30.
- Konstam M.A., Weir A.R. Current persective on the cardiovascular effects of coxibs. Clev Clin J Med 2002; Suppl. 1: 47–52.
- Strand V, Hochberg M.C. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum (Arthritis Care & Res) 2002; 47: 349–55.
- White W.B., Faich G, Borer J.S., Makuch R. Cardiovascular thrombotic events are not increased on the cyclooxygenase-2 inhibitor – celecoxib. ACR 66th Annual Scientific Meeting, New Orleans 2002; 485.
- Reicin A.S., Shapiro D, Sperlong R.S. et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti - inflammatory druds (ibuprofen, diclofenac and nabumeton). Am Cardiol 2002; 89: 204–9.
- Singh G.S., Garnier P, Hwang E. et al. Meloxicam does not increase the risk of cardiovascular adverse events compared to other NSAIDs: results from the IMPROVE trial, a multi - center, randomized parallel - group, open label study of 1309 patients in a managed case setting. EULAR Annual Congress of Rheumatology, Stockholm. Sweden, THU0259 (abst).
- Strand V. Are COX-2 inhibitors preferable to non - selective non - steroidal anti - inflammatory drugs in patients with risk of cardiovascular events taking low - dose aspirin? Lancet 2007; 22; 370 (9605): 2138–51.
- Singh G, Graham D, Wang H. et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non - selective nonsteroidal anti - inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61.
- Knijff-Dutmer E.A.J., Kalsbeek-Batenburg E.M., Koerts J, van Laar M.A.F.J. Platelet function is inhibited by non - selective non - steroidal anti - inflammatory drugs but not by cyclo - oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002; 41: 458–61.
- Сatella-Lawson F, Reilly M.P., Kapoor S.C. et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med 2001; 345: 1809–17.
- Van Solingen R.M., Rosenstein E.D., Mihailescu G. et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am J Med 2001; 111: 285–9.
- Ouellett M, Riendeau D, Percival D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced intereference of platelet cyclooxygenase-1 inactivation by aspirin. PNAS 2001; 98: 14583–8.
- Greenberg H, Gottesdiener K, Huntington M. et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low - dose aspirin in healthy volunteers. J Clin Pharm 2000; 40: 1509–15.
- Derry S, Loke Y.K. Risk of gastrointestinal haemorrage with long term use of aspirin. BMJ 2000; 321: 1183–7.
- Deeks J.J., Smith L.A., Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecocib for treatment of osteoarthritis and rheumatoid arthritis: systemic review of randomized controlled trials. BMJ 2002; 325: 1–8.
- Goldstein H, Bello A, Fort J. et al. Differential rates of UGI symptoms in patients receiving celecoxib vs rofecoxib with and without low - dose aspirin for cardiovascular prophylaxis. EULAR Annual Congress of Rheumatology, Stockholm. Sweden, THU0246 (abst).
- Singh G, Goldstein J, Bello A. et al. Efect of concurrent low - dose aspirin use on the incidence of UGI symptoms in patients receiving celecoxib or conventional NSAIDs: analysis of two largr randomized, double - blind controlled clinical studies. 2002 EULAR Annual Congress of Rheumatology, Stockholm. Sweden, THU0267 (abst).
- Chenevard R, Hurlimann D, Bechir M. et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107.
- Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26.
- Tousoulis D, Davies G, Stefanadis et al. CInflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993–7.
- Baker C.S., Hall R.J., Evans T.J. et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages. Atheroscler Thromb Vasc Biol 1999; 19: 646–55.
- Schonbeck U, Sukhova G.K., Graber P. et al. Augmented expression of cyclooxigenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281–91.
- Burleigh M.E., Babaev V.R., Oates J.A. et al. Cyclooxygenase 2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice. Circulation 2002; 105: 1816–23.
- Cippilone F, Prontera C, Pini B et al. Overexpression of functionally coupled cyclooxygenase Esynthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2–dependent plaque instability. Circulation 2001; 104: 921–30.
- Belton O, Byrne D, Kearney D et al. Cyclooxygenase-1 and – 2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840–5.
Дополнительные файлы
